TP53 and neoplasm: Together, these data indicate that (i) Wnt activation and p53 loss cooperate in promoting overgrowth in RasG12V tumours and (ii) canonical NF-κB signalling reduces trametinib efficacy by primarily modulating host survival rather than tumour growth in Drosophila.